These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8960852)

  • 1. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.
    Rosenkranz B; Profozic V; Metelko Z; Mrzljak V; Lange C; Malerczyk V
    Diabetologia; 1996 Dec; 39(12):1617-24. PubMed ID: 8960852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.
    Shukla UA; Chi EM; Lehr KH
    Ann Pharmacother; 2004 Jan; 38(1):30-5. PubMed ID: 14742789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
    Rosenkranz B
    Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects.
    Sana T; Aslam B; Aslam N; Ashraf MM; Ashraf A; Malik TA; Niazi SG; Tahir IM; RiazurRehman M; Ahmed H
    Pak J Pharm Sci; 2016 Nov; 29(6 Suppl):2321-2326. PubMed ID: 28167473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing.
    Matsuki M; Matsuda M; Kohara K; Shimoda M; Kanda Y; Tawaramoto K; Shigetoh M; Kawasaki F; Kotani K; Kaku K
    Endocr J; 2007 Aug; 54(4):571-6. PubMed ID: 17603225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
    Langtry HD; Balfour JA
    Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers.
    Malerczyk V; Badian M; Korn A; Lehr KH; Waldhäusl W
    Drug Metabol Drug Interact; 1994; 11(4):341-57. PubMed ID: 12369757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
    Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
    Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study.
    Shin KH; Kim SE; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
    Clin Ther; 2011 Nov; 33(11):1809-18. PubMed ID: 22036245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic modeling of glimepiride plasma concentration in healthy subjects.
    Antonesi IM; Potur R; Potur DM; Ghiciuc CM; Lupuşoru CE
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):949-53. PubMed ID: 22046814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
    Smulders RA; Zhang W; Veltkamp SA; van Dijk J; Krauwinkel WJ; Keirns J; Kadokura T
    Diabetes Obes Metab; 2012 Oct; 14(10):937-43. PubMed ID: 22587345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 1998 Oct; 32(10):1044-52. PubMed ID: 9793597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glimepiride--an oral antidiabetic agent].
    Becić F; Kapić E; Becić E
    Med Arh; 2003; 57(2):125-7. PubMed ID: 12822388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects.
    Ju G; Yan K; Xu Y; Chen S; Zheng Z; Qiu W
    Drug Des Devel Ther; 2020; 14():2637-2644. PubMed ID: 32753845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
    Suzuki K; Yanagawa T; Shibasaki T; Kaniwa N; Hasegawa R; Tohkin M
    Diabetes Res Clin Pract; 2006 May; 72(2):148-54. PubMed ID: 16325295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.